Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bird, J. E.
Right arrow Articles by Durham, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bird, J. E.
Right arrow Articles by Durham, S. K.

Journal of the American Society of Nephrology, Vol 7, 1153-1157, Copyright © 1996 by American Society of Nephrology


REGULAR ARTICLES

Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors

JE Bird, MR Giancarli, JR Megill and SK Durham
Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA.

A role for endothelin in the pathogenesis of radiocontrast-induced nephropathy has been suggested by several studies, but the specific contributions of endothelin-A and endothelin-B receptors to the changes in renal function induced by endothelin in this form of renal failure have not been defined. This study examined the effects of the nonselective endothelin receptor antagonist SB-209,670, and the less potent, but selective, endothelin-A receptor antagonist BMS-182,874 in radiocontrast-induced nephropathy in rats. The doses used in this study were chosen from pressor testing data. BMS-182,874 (100 mumol/kg, iv) and SB-209,670 (30 mumol/kg, iv) maximally inhibited the endothelin-1- induced pressor response in rats. BMS-182,874 had no effect on the endothelin-B-mediated depressor response, whereas SB-209,670 abolished it. These results suggest that this is an endothelin-A selective dose of BMS-182,874, and an endothelin-A/B inhibitory dose of SB-209,670. Radiocontrast-induced nephropathy was produced in anesthetized rats (N = 6/group) by intravenous injection of indomethacin (5.0 mg/kg), the nitric oxide synthesis inhibitor N-nitro-L-arginine methyl ester (10.0 mg/kg), vehicle or antagonist, and the radiocontrast agent lopamidol (2,9 g iodine/kg). GFR was partially protected (P < 0.05) by BMS- 182,874 (-43 +/- 3.0% change from baseline) compared with vehicle (-65 +/- 6.0%). The decrease in GFR in SB-209,670-treated rats that received lopamidol was intermediate between the other two groups. The fall in RPF induced by lopamidol was unchanged by either antagonist. The marked diuresis in lopamidol treated rats (630 +/- 125.1%) was reduced (P < 0.01) by BMS-182,874 (176 +/- 77.1%) or SB-209,670 (173 +/- 60.1%). Kidneys were collected for histopathologic evaluation approximately 1 h after lopamidol administration, and the percentage of medullary tubular ascending limbs (mTAL) with morphologic features of necrosis were enumerated by semiquantitative analysis. The percentage of mTAL necrosis was significantly decreased in the BMS-182,874- or SB-209,670- treated rats (P < 0.01) compared with vehicle plus lopamidol-treated animals. In summary, endothelin-A receptor blockade with a highly selective, well-characterized endothelin-A receptor antagonist partly protected GFR, and reduced the marked diuresis and mTAL necrosis in radiocontrast-induced nephropathy in rats. Administration of a nonselective endothelin receptor antagonist provided essentially equivalent ameliorative effects in this model, suggesting that blockade of endothelin-B receptors did not yield any additional protection. These results are consistent with the hypothesis that endothelin-A receptors mediate endothelin-induced changes in renal function and structure in this acute model of radiocontrast-induced nephropathy.


This article has been cited by other articles:


Home page
CJASNHome page
S. N. Heyman, S. Rosen, and C. Rosenberger
Renal Parenchymal Hypoxia, Hypoxia Adaptation, and the Pathogenesis of Radiocontrast Nephropathy
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 288 - 296.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. A. Terlouw, C. Graeff, P. H. E. Smeets, G. Fricker, F. G. M. Russel, R. Masereeuw, and D. S. Miller
Short- and Long-Term Influences of Heavy Metals on Anionic Drug Efflux from Renal Proximal Tubule
J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 578 - 585.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. L. Haylor and S. K. Morcos
An oral ETA-selective endothelin receptor antagonist for contrast nephropathy?
Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1336 - 1337.
[Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. A. Terlouw, R. Masereeuw, F. G. M. Russel, and D. S. Miller
Nephrotoxicants Induce Endothelin Release and Signaling in Renal Proximal Tubules: Effect on Drug Efflux
Mol. Pharmacol., June 1, 2001; 59(6): 1433 - 1440.
[Abstract] [Full Text]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP